Ep 82: Best of ASCO: 2026
Melanoma Matters

Ep 82: Best of ASCO: 2026

2026年6月13日1小时 4分钟

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications. They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes. Studies discussed include: OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy

播放本集

这一集暂时还没有文字稿

你仍然可以在播放器中收听。有文字稿的节目,点任意单词就能看到释义。